Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
Milestone Pharmaceuticals (Nasdaq: MIST) has appointed Joseph Papa to its Board of Directors, effective September 3, 2024. Papa brings over 35 years of experience in the pharmaceutical and healthcare industry, having served as Chairman and CEO of Bausch + Lomb, Bausch Health, and Perrigo. His expertise includes navigating companies through rapid growth, transformation, and strategic M&A transactions.
Robert J. Wills, Chairman of Milestone's Board, expressed enthusiasm for Papa's addition, citing his track record in driving growth and extensive experience across biopharmaceutical companies. Papa's appointment comes as Milestone prepares for the potential approval of CARDAMYST™ (etripamil nasal spray) for paroxysmal supraventricular tachycardia. Papa expressed excitement about joining Milestone, praising the company's leadership, innovation culture, and commitment to improving lives of people with heart conditions.
Milestone Pharmaceuticals (Nasdaq: MIST) ha nominato Joseph Papa nel suo Consiglio di Amministrazione, con effetto dal 3 settembre 2024. Papa porta con sé oltre 35 anni di esperienza nel settore farmaceutico e delle cure sanitarie, avendo ricoperto i ruoli di Presidente e CEO di Bausch + Lomb, Bausch Health e Perrigo. La sua esperienza include la guida delle aziende attraverso rapidi periodi di crescita, trasformazione e transazioni strategiche di M&A.
Robert J. Wills, Presidente del Consiglio di Milestone, ha espresso entusiasmo per l'aggiunta di Papa, citando il suo curriculum nella promozione della crescita e la sua vasta esperienza nel settore delle biofarmaceutiche. La nomina di Papa arriva mentre Milestone si prepara per la potenziale approvazione di CARDAMYST™ (spray nasale di etripamil) per la tachicardia sopraventricolare parossistica. Papa ha espresso entusiasmo per l'ingresso in Milestone, lodando la leadership dell'azienda, la cultura dell'innovazione e l'impegno a migliorare la vita delle persone con condizioni cardiache.
Milestone Pharmaceuticals (Nasdaq: MIST) ha designado a Joseph Papa para su Junta Directiva, con efecto a partir del 3 de septiembre de 2024. Papa aporta más de 35 años de experiencia en la industria farmacéutica y de atención médica, habiendo sido Presidente y CEO de Bausch + Lomb, Bausch Health y Perrigo. Su experiencia incluye la conducción de empresas a través de un rápido crecimiento, transformación y transacciones estratégicas de M&A.
Robert J. Wills, Presidente de la Junta de Milestone, expresó entusiasmo por la incorporación de Papa, destacando su historial en impulsar el crecimiento y su amplia experiencia en empresas biofarmacéuticas. La designación de Papa se produce mientras Milestone se prepara para la potencial aprobación de CARDAMYST™ (spray nasal de etripamil) para la taquicardia supraventricular paroxística. Papa expresó su emoción por unirse a Milestone, elogiando el liderazgo de la compañía, la cultura de innovación y el compromiso de mejorar la vida de las personas con afecciones cardíacas.
Milestone Pharmaceuticals(Nasdaq: MIST)는 Joseph Papa를 이사회의 일원으로 임명했으며, 이는 2024년 9월 3일부터 유효합니다. Papa는 35년 이상의 경험을 보유하고 있으며, Bausch + Lomb, Bausch Health 및 Perrigo의 회장 및 CEO를 역임했습니다. 그의 전문성은 빠른 성장, 변혁 및 전략적 M&A 거래를 통해 회사를 이끄는 것을 포함합니다.
Milestone 이사회의 의장인 Robert J. Wills는 Papa의 합류에 대해 열정을 표명하며, 그의 성장 촉진 실적과 생물의약품 기업 전반의 광범위한 경험을 강조했습니다. Papa의 임명은 Milestone이 CARDAMYST™ (에트리파밀 비강 스프레이)의 기회적 심장초음파 치료를 위한 잠재적 승인을 준비하는 가운데 이루어졌습니다. Papa는 Milestone에 합류하게 된 것에 대해 기쁨을 표명하며, 회사의 리더십, 혁신 문화 및 심장 질환 환자들의 삶을 개선하는 데 대한 헌신을 칭찬했습니다.
Milestone Pharmaceuticals (Nasdaq: MIST) a nommé Joseph Papa au sein de son Conseil d'administration, avec effet à partir du 3 septembre 2024. Papa apporte plus de 35 ans d'expérience dans l'industrie pharmaceutique et des soins de santé, ayant été Président et CEO de Bausch + Lomb, Bausch Health et Perrigo. Son expertise comprend la gestion des entreprises lors de croissances rapides, de transformations et de transactions stratégiques de fusions-acquisitions.
Robert J. Wills, Président du Conseil de Milestone, a exprimé son enthousiasme pour l'ajout de Papa, en soulignant son parcours en matière de croissance et sa vaste expérience au sein d'entreprises biopharmaceutiques. La nomination de Papa intervient alors que Milestone se prépare à la potentielle approbation de CARDAMYST™ (spray nasal d'étripamil) pour la tachycardie supraventriculaire paroxystique. Papa a exprimé sa joie de rejoindre Milestone, louant le leadership de l'entreprise, sa culture d'innovation et son engagement à améliorer la vie des personnes souffrant de maladies cardiaques.
Milestone Pharmaceuticals (Nasdaq: MIST) hat Joseph Papa in seinen Vorstand berufen, wirksam ab dem 3. September 2024. Papa bringt über 35 Jahre Erfahrung in der Pharma- und Gesundheitsbranche mit, nachdem er als Vorsitzender und CEO von Bausch + Lomb, Bausch Health und Perrigo tätig war. Seine Expertise umfasst die Navigation durch schnelles Wachstum, Transformation und strategische M&A-Transaktionen.
Robert J. Wills, Vorsitzender des Vorstands von Milestone, äußerte Begeisterung über Papas Addition und hob dessen Erfolgsbilanz bei der Förderung von Wachstum sowie seine umfangreiche Erfahrung in biopharmazeutischen Unternehmen hervor. Papas Berufung erfolgt, während Milestone sich auf die mögliche Genehmigung von CARDAMYST™ (Etripamil-Nasenspray) zur Behandlung von paroxysmaler supraventrikulärer Tachykardie vorbereitet. Papa äußerte seine Freude über den Eintritt bei Milestone und lobte die Unternehmensführung, die Innovationskultur und das Engagement zur Verbesserung des Lebens von Menschen mit Herzkrankheiten.
- Appointment of Joseph Papa, an industry veteran with 35+ years of experience, to the Board of Directors
- Papa's expertise in navigating companies through rapid growth and strategic M&A transactions
- Potential upcoming approval of CARDAMYST™ for paroxysmal supraventricular tachycardia
- None.
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024.
Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings broad commercial experience and proven capabilities of advancing innovative products aimed at significantly enhancing patients’ lives.
“Joe is an accomplished leader with a track record of driving growth, and we are thrilled to welcome him to our Board,” said Robert J. Wills, PhD, Chairman of the Board of Milestone. “His tremendous experience across an extensive range of biopharmaceutical companies and products provides a skillset that is an excellent complement to the existing board. We look forward to his strategic guidance as we prepare for potential approval of our investigational drug CARDAMYST™ (etripamil nasal spray) for paroxysmal supraventricular tachycardia.”
Mr. Papa commented, “I am very impressed by Milestone’s leadership team, culture of innovation, and commitment to improving the lives of people with life-altering heart conditions. I see a great opportunity for value creation and look forward to collaborating with the Board and the team to advance CARDAMYST and, if approved, to help bring this much needed treatment to patients.”
About Joseph Papa
Joseph Papa has over 35 years of experience in the pharmaceutical, healthcare and specialty pharmaceutical industries. Since February 2024, he has served as Chief Executive Officer of Emergent BioSolutions (NYSE: EBS). He served as Chief Executive Officer of Bausch + Lomb Corporation from May 2022 to March 2023 to facilitate a smooth leadership transition. Previously, Mr. Papa served as Chairman and CEO of Bausch Health from 2016 to 2022, where he oversaw the company’s rapid growth and spin-off of Bausch + Lomb. From 2006 to 2016, Mr. Papa served as Chairman and CEO of Perrigo. Prior to Perrigo, Mr. Papa served as President of PTS for Cardinal Health, President of Watson Pharmaceuticals, President of U.S. operations for Searle/Pharmacia, Chief Operating Officer of DuPont Pharmaceuticals and Vice President of Marketing for Novartis. He currently serves as Chair of the board of directors of SparingVision, a privately held genomic medicines company, and as a member of the board of directors of Candel Therapeutics (Nasdaq: CADL), a clinical stage biopharmaceutical company developing immunotherapies for cancer patients, where he chairs the compensation committee. He previously served on the boards of directors of Prometheus Biosciences, as lead independent director and chair of the compensation committee until the company’s sale to Merck in 2023, and Smith & Nephew plc as chair of the remuneration committee. Mr. Papa holds a B.S. in pharmacy from the University of Connecticut and an M.B.A. from Northwestern University’s Kellogg Graduate School of Management.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Forward-Looking Statements
This press release contains forward-looking statements and forward looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws (“forward looking statements”). Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will”, “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the timing of upcoming clinical trial milestones and related data; the timing of the FDA’s review of the NDA and the FDA’s potential approval of CARDAMYST; the potential of etripamil to help patients living with these serious heart arrythmias; and the timing of the launch of etripamil. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; whether the FDA will require additional trials or data which may significantly delay and put at risk our efforts to obtain approval and may not be successful, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission (SEC) and the Canadian securities regulatory authorities, including in its annual report on Form 10-K for the year ended December 31, 2024, under the caption “Risk Factors,” as such discussion may be updated from time to time by subsequent filings Milestone may make with the SEC and the Canadian securities regulatory authorities, which is available under Milestone’s profile on EDGAR at www.sec.gov and on SEDAR at www.sedarplus.ca. Except as required by applicable law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available or based on future events or otherwise.
Contact:
Kim Fox, Vice President, Communications,
kfox@milestonepharma.com
Investor Relations
Chris Calabrese,
ccalabrese@lifesciadvisors.com
Kevin Gardner,
kgardner@lifesciadvisors.com
FAQ
Who is the new board member appointed by Milestone Pharmaceuticals (MIST)?
What is CARDAMYST™ and what is its current status for Milestone Pharmaceuticals (MIST)?
What experience does Joseph Papa bring to Milestone Pharmaceuticals (MIST)?
When did Joseph Papa join the Board of Directors of Milestone Pharmaceuticals (MIST)?
